about
Trastuzumab combined with docetaxel-based regimens in previously treated metastatic gastric cancer patients with HER2 over-expression.Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.Anti-angiogenic therapy with contrast-enhanced ultrasound in colorectal cancer patients with liver metastasis.HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy.Timing of chemotherapy-induced neutropenia predicts prognosis in metastatic colon cancer patients: a retrospective study in mFOLFOX6 -treated patientsAspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinomaDietary Patterns and Risk of Colorectal Cancer: Analysis by Tumor Location and Molecular Subtypes.Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location.MicroRNA let-7, T Cells, and Patient Survival in Colorectal Cancer.Association Between Inflammatory Diet Pattern and Risk of Colorectal Carcinoma Subtypes Classified by Immune Responses to Tumor.Tumor SQSTM1 (p62) expression and T cells in colorectal cancer.Tumour CD274 (PD-L1) expression and T cells in colorectal cancer.MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.Leucine-rich alpha-2-glycoprotein-1, relevant with microvessel density, is an independent survival prognostic factor for stage III colorectal cancer patients: a retrospective analysis.Timing of chemotherapy-induced neutropenia: the prognostic factor in advanced pancreatic cancer patients treated with gemcitabine / gemcitabine-based chemotherapyHistone demethylase PHF8 accelerates the progression of colorectal cancer and can be regulated by miR-488 in vitro.Sorafenib combined with TACE in advanced primary hepatocellular carcinoma.Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells.Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index.Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with advanced gastric cancer undergoing first-line chemotherapy with oxaliplatin and capecitabine: a retrospective study.Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma.Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
P50
Q33400932-AA9B7D9E-F343-4D5D-9D40-1517A447B74CQ33677891-42ABDE1B-C7C2-42A2-B1E5-297782F4D489Q33714320-04DF8444-BD96-4D0F-914A-8411620439E6Q35116307-224E26F2-30E2-4574-BEA2-B2BC09B0F742Q36334640-649B0916-C3F3-4C58-A4F7-7D5A6C3DC96AQ36345775-EAA17A08-F5BA-45AE-87F6-DA95CCB83205Q36891363-87FD5BE1-22BC-4E5E-9307-41A3AD702152Q38935141-5482EACE-F57B-4E18-A12F-3A494658D76DQ39217446-FD688B3A-96A2-4352-AD62-15F589A2CC3FQ39294187-739F54B2-DE5F-447A-951F-0B1F8FA5427FQ40060444-8DDC53F5-4294-419E-A469-AB8681151AF1Q40244514-CA4A0634-628A-45C9-95DA-66CCE3A3FCC4Q40746149-4DDC50E1-1E1E-4DFB-BB8E-0E57A40610D5Q40864425-6AD7957B-FA03-4142-996E-8AC25D1837E7Q42371665-AF5A0436-26F9-44AB-9AE9-D3D38A1A979CQ42371672-22212FA3-B3DF-46CB-8DB7-E927EF5E8EA6Q42679361-1D926BAD-7ADA-460C-9E75-6A6ED544BE9EQ44550053-F16C1454-1527-464D-BD84-7B57CB0DFF6DQ46065007-6B12527B-00DB-4356-823C-96251D60A987Q47171553-17586D2E-156E-458C-B87D-E0C11C8AD873Q47677607-7DE2B0A6-F672-44FE-9DA5-DCD43371D03FQ50077322-7232F131-0C83-401C-A59A-77CC45B06227Q52658505-4C707AE9-3D5A-46B7-8694-FBDD28E1CAF3Q54589838-A2DDBDE1-47D9-4D5E-9768-E4BF5C3AA678Q54632156-9F2C5A60-B4AF-48C2-AC72-829F8FAC2264
P50
description
researcher ORCID: 0000-0001-9777-8836
@en
name
Yan Shi
@ast
Yan Shi
@en
Yan Shi
@es
Yan Shi
@nl
type
label
Yan Shi
@ast
Yan Shi
@en
Yan Shi
@es
Yan Shi
@nl
prefLabel
Yan Shi
@ast
Yan Shi
@en
Yan Shi
@es
Yan Shi
@nl
P106
P31
P496
0000-0001-9777-8836